<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-153867</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Mantle cell lymphoma, response to treatment and prognosis in 45 patients</dc:title>
<dc:description xml:lang="en">Background and purpose Mantle cell lymphoma (MCL) is a rare lymphoproliferative disorder, with frequent relapses and a poor prognosis. This study analyzes response to treatment and prognosis in a series of MCL patients. Patients and method: Retrospective study of MCL patients diagnosed in a single institution between 1996 and 2013. The cohort was divided according to the treatment received. Results: Forty-five patients were included (32 male) with a median age of 66 years old. Twenty-one received intensive chemotherapy or chemoimmunotherapy (based on high-dose cytarabine), 13 semi-intensive (without high-dose cytarabine), 8 not intensive and 3 did not require treatment. Overall response rate was 85% in the intensive and 77% in the semi-intensive treatment groups. In multivariate analysis, intensive treatment was correlated with a longer progression-free survival (hazard ratio 9.8 [95% CI 2.7-35.5], P = .001) and overall survival (4.5 [1.2-17.8], P = .03). Conclusions: In this retrospective series of MCL patients, intensive treatment was correlated with better outcomes than the other treatment modalities (AU)</dc:description>
<dc:creator>Sorigue, Marc</dc:creator>
<dc:creator>García, Olga</dc:creator>
<dc:creator>Sancho, Juan Manuel</dc:creator>
<dc:creator>Moreno, Miriam</dc:creator>
<dc:creator>Vila, Jordi</dc:creator>
<dc:creator>Ribera, Josep Maria</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Fundamento y objetivo: El linfoma de células del manto (LCM) es un linfoma poco frecuente, con recaídas habituales y mal pronóstico. Este estudio analiza la respuesta al tratamiento y el pronóstico en una serie de pacientes con LCM. Pacientes y método: Estudio retrospectivo de los pacientes con LCM diagnosticados en un centro entre 1996 y 2013. Se dividió la cohorte en función del tratamiento recibido. Resultados: Se incluyeron 45 pacientes (32 varones) con una edad mediana de 66 años. Veintiún pacientes recibieron quimioterapia o quimioinmunoterapia intensiva (pautas con citarabina a dosis altas), 13 semiintensiva (sin citarabina a dosis altas), 8 no intensiva y 3 no precisaron tratamiento. La respuesta global fue del 85% con tratamiento intensivo y del 77% con semiintensivo. En el análisis multivariable el tratamiento intensivo se asoció a una mayor probabilidad de supervivencia libre de progresión (SLP) y supervivencia global (SG) (hazard ratio de 9,8 [IC 95% 2,7-35,5], p = 0,001 para la SLP y 4,5 [1,2-17,8], p = 0,03 para la SG). Conclusiones: En esta serie retrospectiva de pacientes con LCM el tratamiento intensivo se asoció a mejores resultados respecto al resto de las modalidades de tratamiento (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);147(1): 18-21, jul. 2016. graf</dc:source>
<dc:identifier>ibc-153867</dc:identifier>
<dc:title xml:lang="es">Linfoma de células del manto. Respuesta al tratamiento y pronóstico en 45 pacientes</dc:title>
<dc:subject>^d34176^s22016</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d11812</dc:subject>
<dc:subject>^d34176^s22067</dc:subject>
<dc:subject>^d4365</dc:subject>
<dc:subject>^d34176^s22054</dc:subject>
<dc:subject>^d34176^s22032</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d3578^s22044</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d24023^s22073</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d3540^s22073</dc:subject>
<dc:subject>^d22622^s22073</dc:subject>
<dc:subject>^d3578^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d35067^s22045</dc:subject>
<dc:subject>^d34176^s22080</dc:subject>
<dc:type>article</dc:type>
<dc:date>201607</dc:date>
</metadata>
</record>
</ibecs-document>
